Takeda sees continuing growth from emerging markets
This article was originally published in Scrip
Executive Summary
Overseas acquisitions and growth in emerging markets both helped Takeda weather the destruction of its US Actos (pioglitazone) franchise in the first quarter ended 30 June, when US sales of the oral antidiabetic slumped by $554m on generic competition.